430 related articles for article (PubMed ID: 33351271)
1. Potential of Nociceptin/Orphanin FQ Peptide Analogs for Drug Development.
Wtorek K; Janecka A
Chem Biodivers; 2021 Jan; 18(1):e2000871. PubMed ID: 33351271
[TBL] [Abstract][Full Text] [Related]
2. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
3. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic.
Thompson AA; Liu W; Chun E; Katritch V; Wu H; Vardy E; Huang XP; Trapella C; Guerrini R; Calo G; Roth BL; Cherezov V; Stevens RC
Nature; 2012 May; 485(7398):395-9. PubMed ID: 22596163
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological activity of small peptides as NOP and opioid receptors' ligands: view on current developments.
Naydenova E; Todorov P; Zamfirova R
Vitam Horm; 2015; 97():123-46. PubMed ID: 25677770
[TBL] [Abstract][Full Text] [Related]
5. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
Tzschentke TM; Rutten K
Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
[TBL] [Abstract][Full Text] [Related]
6. Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ.
Donica CL; Awwad HO; Thakker DR; Standifer KM
Mol Pharmacol; 2013 May; 83(5):907-18. PubMed ID: 23395957
[TBL] [Abstract][Full Text] [Related]
7. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications.
Chiou LC; Liao YY; Fan PC; Kuo PH; Wang CH; Riemer C; Prinssen EP
Curr Drug Targets; 2007 Jan; 8(1):117-35. PubMed ID: 17266536
[TBL] [Abstract][Full Text] [Related]
8. Helix-constrained nociceptin peptides are potent agonists and antagonists of ORL-1 and nociception.
Lohman RJ; Harrison RS; Ruiz-Gómez G; Hoang HN; Shepherd NE; Chow S; Hill TA; Madala PK; Fairlie DP
Vitam Horm; 2015; 97():1-55. PubMed ID: 25677767
[TBL] [Abstract][Full Text] [Related]
9. Quantitative study of [Tyr10]nociceptin/orphanin FQ (1-11) at NOP receptors in rat periaqueductal gray and expressed NOP receptors in HEK293 cells.
Liao YY; Lee CW; Ho IK; Chiou LC
Life Sci; 2012 Feb; 90(7-8):306-12. PubMed ID: 22213115
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of nociceptin/orphanin FQ receptors, a novel opioid receptor family, in the midbrain periaqueductal gray.
Chiou LC; Fan SH; Chuang KC; Liao YY; Lee SZ
Ann N Y Acad Sci; 2004 Oct; 1025():398-403. PubMed ID: 15542742
[TBL] [Abstract][Full Text] [Related]
11. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.
Guerrini R; Caló G; Lambert DG; Carrá G; Arduin M; Barnes TA; McDonald J; Rizzi D; Trapella C; Marzola E; Rowbotham DJ; Regoli D; Salvadori S
J Med Chem; 2005 Mar; 48(5):1421-7. PubMed ID: 15743186
[TBL] [Abstract][Full Text] [Related]
12. Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy?
Zeilhofer HU; Calò G
J Pharmacol Exp Ther; 2003 Aug; 306(2):423-9. PubMed ID: 12721334
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).
Bird MF; Cerlesi MC; Brown M; Malfacini D; Vezzi V; Molinari P; Micheli L; Di Cesare Mannelli L; Ghelardini C; Guerrini R; Calò G; Lambert DG
PLoS One; 2016; 11(6):e0156897. PubMed ID: 27272042
[TBL] [Abstract][Full Text] [Related]
14. Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity.
Guerrini R; Carra' G; Calo' G; Trapella C; Marzola E; Rizzi D; Regoli D; Salvadori S
J Pept Res; 2004 Jun; 63(6):477-84. PubMed ID: 15175020
[TBL] [Abstract][Full Text] [Related]
15. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
Calo G; Rizzi A; Rizzi D; Bigoni R; Guerrini R; Marzola G; Marti M; McDonald J; Morari M; Lambert DG; Salvadori S; Regoli D
Br J Pharmacol; 2002 May; 136(2):303-11. PubMed ID: 12010780
[TBL] [Abstract][Full Text] [Related]
16. Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux.
D'Agostino B; Marrocco G; De Nardo M; Calò G; Guerrini R; Gallelli L; Advenier C; Rossi F
Br J Pharmacol; 2005 Mar; 144(6):813-20. PubMed ID: 15685213
[TBL] [Abstract][Full Text] [Related]
17. Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.
Toll L; Bruchas MR; Calo' G; Cox BM; Zaveri NT
Pharmacol Rev; 2016 Apr; 68(2):419-57. PubMed ID: 26956246
[TBL] [Abstract][Full Text] [Related]
18. Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-activity relationships for (4-arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives.
Hayashi S; Ohashi K; Mihara S; Nakata E; Emoto C; Ohta A
Eur J Med Chem; 2016 May; 114():345-64. PubMed ID: 27043173
[TBL] [Abstract][Full Text] [Related]
19. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
[TBL] [Abstract][Full Text] [Related]
20. UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor.
Calo G; Guerrini R; Rizzi A; Salvadori S; Burmeister M; Kapusta DR; Lambert DG; Regoli D
CNS Drug Rev; 2005; 11(2):97-112. PubMed ID: 16007234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
